Patient characteristics, including baseline plasma NT-proBNP level and left atrial diameter, also did not differ between patients with successful cardioversion with flecainide who still had SR and patients with successful cardioversion with flecainide in whom AF had recurred at follow-up (Table 3). This evidence concerns the gene NPPB and atrial fibrillation.